Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Cash: 2014-2025

Historic Change in Cash for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $52.3 million.

  • Viridian Therapeutics, Inc.\DE's Change in Cash fell 43.53% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year decrease of 134.57%. This contributed to the annual value of -$3.2 million for FY2024, which is 93.87% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Change in Cash is $52.3 million, which was up 4,618.03% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Cash peaked at $312.9 million during Q3 2022, and registered a low of -$188.6 million during Q4 2022.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Change in Cash had a median value of $1.1 million in 2025 and averaged $1.3 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Change in Cash skyrocketed by 22,201.39% in 2021 and then slumped by 2,032.60% in 2022.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Change in Cash stood at -$96.6 million in 2021, then slumped by 95.32% to -$188.6 million in 2022, then surged by 95.35% to -$8.8 million in 2023, then crashed by 1,048.49% to -$100.7 million in 2024, then slumped by 43.53% to $52.3 million in 2025.
  • Its Change in Cash was $52.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $16.6 million in Q1 2025.